01/04/2026
Obesity Care
GLP-1 medications have signalled a new phase in obesity management. BUT... are we truly addressing the root of the problem, or simply shifting the focus?
A recent joint statement from several leading international organisations, including the World Obesity Federation, delivers a clear message - pharmacological treatment cannot, and should never replace lifestyle interventions.
The scale of the issue is striking. Over 38% of adults worldwide are living with overweight or obesity. 69.7% of the Maltese population is either overweight or obese. Obesity is also associated with more than 250 related health conditions. Within this context, GLP-1 medications represent a powerful and valuable tool. However, when used in isolation, without integration with physical activity and nutrition, they risk becoming an incomplete solution.
A purely pharmacological approach carries several concerns. These include potential loss of muscle mass and functional capacity, limited long-term sustainability, and the risk of widening existing health inequalities. Importantly, it also overlooks the well-established mental, social, and physiological benefits of movement.
The challenge we face is not solely pharmacological, but systemic.
What is required is a shift in approach, towards integrated care models, equitable access to opportunities for physical activity, nutritious food, and professional support.
Success should not be measured by weight alone, but by broader outcomes such as quality of life, physical strength, and functional independence.
Ultimately, the goal is not to choose between medication and lifestyle, but to create a cohesive system in which both work in synergy.
Which brings us to the question...Are we moving towards an advanced obesity care model? Or a dependent one?
